A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

BACKGROUND: The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory effects....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Turnbull, Catriona M, Marcarino, Paolo, Sheldrake, Tara A, Lazzarato, Loretta, Cena, Clara, Fruttero, Roberta, Gasco, Alberto, Fox, Sarah, Megson, Ian L, Rossi, Adriano G
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2008
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2525633/
https://ncbi.nlm.nih.gov/pubmed/18671842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-9255-5-12
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados